Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04466215 · ClinicalTrials.gov registry record · Phase 2
Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
A Phase 2 study of Alcohol Use Disorder, sponsored by The Scripps Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04466215: Completed Phase 2 study of Alcohol Use Disorder, sponsored by The Scripps Research Institute.
NCT04466215 is a Phase 2 study of Alcohol Use Disorder that has completed, run by The Scripps Research Institute. The registered enrollment target is 50 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04466215, a Phase 2 study of Alcohol Use Disorder, has completed, sponsored by The Scripps Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypotheses under test are that subjects with alcohol use disorder (AUD) of moderate or greater severity treated with CORT118335 will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo.
Primary Outcome
Total Visual Analog Scale (VAS) scores of craving severity in response to in vivo alcohol cues. Higher scores indicate greater craving severity with a minimum score of 0 and a maximum score of 80.
Conditions Studied
Interventions
- DRUG Placebo oral tablet
- DRUG Miricorilant
Study Locations (1)
California
- The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2022-06-07 |
| Phase | Phase 2 |
What the finished NCT04466215 record still lists
NCT04466215 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04466215 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04466215 about?
NCT04466215 is a clinical study titled "Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo". The hypotheses under test are that subjects with alcohol use disorder (AUD) of moderate or greater severity treated with CORT118335 will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those ...
What is the current status of trial NCT04466215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2021-04-15. Estimated completion is 2022-06-07.
What conditions does trial NCT04466215 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT04466215?
The interventions under investigation include: Placebo oral tablet (DRUG), Miricorilant (DRUG).
Who is sponsoring clinical trial NCT04466215?
This trial is sponsored by The Scripps Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04466215 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04466215's enrollment target sits among peer trials
50 125th of 184 higher than 57 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI